Screener
Immunome IMNM CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash used in operating activities | (58,638) | (53,055) |
| Cash flows from investing activities: | ||
| Purchases of in-process research and development assets | (9,014) | (6,246) |
| Purchases of property and equipment | (3,002) | (3,665) |
| Maturities of marketable securities | — | 15,000 |
| Net cash (used in) provided by investing activities | (12,016) | 5,089 |
| Cash flows from financing activities: | ||
| Proceeds from public offerings | — | 172,500 |
Item 1. Financial Statements.
FAQ
- What is Immunome's capex?
- Immunome (IMNM) reported capex of $3M in Q1 2026.
- How has Immunome's capex changed year-over-year?
- Immunome's capex decreased by 18.1% year-over-year, from $3.67M to $3M.
- What is the long-term trend for Immunome's capex?
- Over 4 years (2021 to 2025), Immunome's capex has grown at a 232.8% compound annual growth rate (CAGR), from $79K to $9.69M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Immunome's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude